476 related articles for article (PubMed ID: 24978425)
1. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease.
Ayabe R; Rootman DB; Hwang CJ; Ben-Artzi A; Goldberg R
Ophthalmic Plast Reconstr Surg; 2014; 30(5):415-9. PubMed ID: 24978425
[TBL] [Abstract][Full Text] [Related]
2. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease.
Shams PN; Ma R; Pickles T; Rootman J; Dolman PJ
Am J Ophthalmol; 2014 Jun; 157(6):1299-305. PubMed ID: 24582992
[TBL] [Abstract][Full Text] [Related]
3. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy.
Currò N; Covelli D; Vannucchi G; Campi I; Pirola G; Simonetta S; Dazzi D; Guastella C; Pignataro L; Beck-Peccoz P; Ratiglia R; Salvi M
Thyroid; 2014 May; 24(5):897-905. PubMed ID: 24417307
[TBL] [Abstract][Full Text] [Related]
5. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.
Díaz-Llopis M; Salom D; Garcia-de-Vicuña C; Cordero-Coma M; Ortega G; Ortego N; Suarez-de-Figueroa M; Rio-Pardo MJ; Fernandez-Cid C; Fonollosa A; Blanco R; Garcia-Aparicio AM; Benitez-Del-Castillo JM; Olea JL; Arevalo JF
Ophthalmology; 2012 Aug; 119(8):1575-81. PubMed ID: 22525047
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy for the treatment of thyroid eye disease-a prospective comparison: Is orbital radiotherapy a suitable alternative to steroids?
Grassi P; Strianese D; Piscopo R; Pacelli R; Bonavolontà G
Ir J Med Sci; 2017 Aug; 186(3):647-652. PubMed ID: 28050807
[TBL] [Abstract][Full Text] [Related]
7. Orbital steroid injection versus oral steroid therapy in management of thyroid-related ophthalmopathy.
Alkawas AA; Hussein AM; Shahien EA
Clin Exp Ophthalmol; 2010 Oct; 38(7):692-7. PubMed ID: 20497432
[TBL] [Abstract][Full Text] [Related]
8. Low dose orbital radiotherapy for thyroid eye disease.
Li Yim JF; Sandinha T; Kerr JM; Ritchie D; Kemp EG
Orbit; 2011 Dec; 30(6):269-74. PubMed ID: 22132844
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab therapy for refractory uveitis: a pilot study.
Diaz-Llopis M; García-Delpech S; Salom D; Udaondo P; Hernández-Garfella M; Bosch-Morell F; Quijada A; Romero FJ
J Ocul Pharmacol Ther; 2008 Jun; 24(3):351-61. PubMed ID: 18476805
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Immunosuppressive Agents for Thyroid Eye Disease.
Strianese D
Ophthalmic Plast Reconstr Surg; 2018; 34(4S Suppl 1):S56-S59. PubMed ID: 29923966
[TBL] [Abstract][Full Text] [Related]
12. Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach.
Sipkova Z; Insull EA; David J; Turner HE; Keren S; Norris JH
Clin Endocrinol (Oxf); 2018 Dec; 89(6):834-839. PubMed ID: 30103255
[TBL] [Abstract][Full Text] [Related]
13. Treatment of active corticosteroid-resistant graves' orbitopathy.
Pérez-Moreiras JV; Alvarez-López A; Gómez EC
Ophthalmic Plast Reconstr Surg; 2014; 30(2):162-7. PubMed ID: 24503568
[TBL] [Abstract][Full Text] [Related]
14. Orbital Radiotherapy Combined With Corticosteroid Treatment for Thyroid Eye Disease-Compressive Optic Neuropathy.
Gold KG; Scofield S; Isaacson SR; Stewart MW; Kazim M
Ophthalmic Plast Reconstr Surg; 2018; 34(2):172-177. PubMed ID: 29517594
[TBL] [Abstract][Full Text] [Related]
15. A three-centre experience with adalimumab for the treatment of non-infectious uveitis.
Dobner BC; Max R; Becker MD; Heinz C; Veltrup I; Heiligenhaus A; Barisani-Asenbauer T; Mackensen F
Br J Ophthalmol; 2013 Feb; 97(2):134-8. PubMed ID: 23212204
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
[TBL] [Abstract][Full Text] [Related]
17. Comparison of lateral and medial orbital decompression for the treatment of compressive optic neuropathy in thyroid eye disease.
Choe CH; Cho RI; Elner VM
Ophthalmic Plast Reconstr Surg; 2011; 27(1):4-11. PubMed ID: 20736873
[TBL] [Abstract][Full Text] [Related]
18. Age differences in clinical manifestation and prognosis of thyroid eye disease.
Ben Simon GJ; Katz G; Zloto O; Leiba H; Hadas B; Huna-Baron R
Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2301-8. PubMed ID: 26344731
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab for thyroid eye disease.
Hamed Azzam S; Kang S; Salvi M; Ezra DG
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012984. PubMed ID: 30480323
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab for orbital myositis in a patient with Crohn's disease who discontinued infliximab: a case report and review of the literature.
Verma S; Kroeker KI; Fedorak RN
BMC Gastroenterol; 2013 Apr; 13():59. PubMed ID: 23556424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
